Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

CD4+ T cell help during early acute hepacivirus infection is critical for viral clearance and the generation of a liver-homing CD103+CD49a+ effector CD8+ T cell subset.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science, c2005-
    • الموضوع:
    • نبذة مختصرة :
      Competing Interests: The authors have declared that no competing interests exist.
      In hepatitis C virus (HCV) infection, CD4+ and CD8+ T cells are crucial for viral control. However, a detailed understanding of the kinetic of CD4+ T cell help and its role in the generation of different CD8+ T cell subsets during acute infection is lacking. The absence of a small HCV animal model has impeded mechanistic studies of hepatic antiviral T cell immunity and HCV vaccine development. In this study, we used a recently developed HCV-related rodent hepacivirus infection mouse model to investigate the impact of CD4+ T cell help on the hepatic CD8+ T cell response and viral clearance during hepacivirus infection in vivo. Our results revealed a specific kinetic of CD4+ T cell dependency during acute infection. Early CD4+ T cell help was essential for CD8+ T cell priming and viral clearance, while CD4+ T cells became dispensable during later stages of acute infection. Effector CD8+ T cells directly mediated timely hepacivirus clearance. An analysis of hepatic CD8+ T cells specific for two different viral epitopes revealed the induction of subsets of liver-homing CD103+CD49a+ and CD103-CD49a+ effector CD8+ T cells with elevated IFN-γ and TNF-α production. CD103+CD49a+ T cells further persisted as tissue-resident memory subsets. A lack of CD4+ T cell help and CD40L-CD40 interactions resulted in reduced effector functions and phenotypical changes in effector CD8+ T cells and a specific loss of the CD103+CD49a+ subset. In summary, our study shows that early CD4+ T cell help through CD40L signaling is essential for priming functional effector CD8+ T cell subsets, including unique liver-homing subsets, and hepacivirus clearance.
      (Copyright: © 2024 Lopez-Scarim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Immunity. 2014 Jul 17;41(1):127-40. (PMID: 25035957)
      J Exp Med. 2021 Apr 5;218(4):. (PMID: 33755719)
      Gut. 2019 May;68(5):905-915. (PMID: 30622109)
      J Hepatol. 2021 Jan;74(1):220-229. (PMID: 33002569)
      J Hepatol. 2022 Nov;77(5):1311-1324. (PMID: 35753523)
      Immunity. 2009 Jul 17;31(1):131-44. (PMID: 19604492)
      Cell. 2015 May 7;161(4):737-49. (PMID: 25957682)
      Nat Rev Immunol. 2022 May;22(5):283-293. (PMID: 34480118)
      Cells. 2021 Apr 23;10(5):. (PMID: 33922441)
      Nat Commun. 2024 Feb 10;15(1):1261. (PMID: 38341416)
      Front Immunol. 2022 Sep 09;13:953151. (PMID: 36159876)
      J Exp Med. 2003 Jun 16;197(12):1645-55. (PMID: 12810686)
      PLoS Pathog. 2023 Oct 9;19(10):e1011697. (PMID: 37812637)
      Annu Rev Immunol. 2024 Jun;42(1):375-399. (PMID: 38360545)
      Immunity. 2017 Nov 21;47(5):848-861.e5. (PMID: 29126798)
      Immunity. 2023 Jul 11;56(7):1664-1680.e9. (PMID: 37392736)
      Immunity. 2018 Apr 17;48(4):716-729.e8. (PMID: 29625895)
      J Immunol. 2009 Apr 1;182(7):4244-54. (PMID: 19299723)
      N Engl J Med. 2021 Feb 11;384(6):541-549. (PMID: 33567193)
      Int J Mol Sci. 2021 Jan 07;22(2):. (PMID: 33430234)
      Lancet. 2023 Sep 23;402(10407):1085-1096. (PMID: 37741678)
      Science. 2017 Jul 14;357(6347):204-208. (PMID: 28706073)
      Cell Rep. 2021 Sep 14;36(11):109696. (PMID: 34525366)
      Hepatology. 2024 Oct 1;80(4):937-950. (PMID: 38214558)
      Immunity. 2019 Nov 19;51(5):840-855.e5. (PMID: 31606264)
      J Virol. 2002 Sep;76(17):8609-20. (PMID: 12163580)
      Front Immunol. 2021 Sep 09;12:728669. (PMID: 34566986)
      J Immunol. 2018 Oct 1;201(7):2176-2186. (PMID: 30143586)
      J Clin Invest. 2021 Apr 1;131(7):. (PMID: 33792560)
      J Hepatol. 2020 Jun;72(6):1170-1181. (PMID: 31987989)
      Viruses. 2019 Jul 26;11(8):. (PMID: 31357397)
      Curr Opin Virol. 2021 Dec;51:80-86. (PMID: 34619514)
      Immunity. 2015 Dec 15;43(6):1101-11. (PMID: 26682984)
      Science. 2003 Oct 24;302(5645):659-62. (PMID: 14576438)
      Nat Protoc. 2014 Jan;9(1):209-22. (PMID: 24385150)
      Sci Immunol. 2017 Mar;2(9):. (PMID: 28707003)
      Nat Rev Immunol. 2016 Feb;16(2):102-11. (PMID: 26781939)
      J Virol. 2001 Oct;75(20):9918-24. (PMID: 11559824)
      Science. 2003 Apr 11;300(5617):339-42. (PMID: 12690202)
      Int J Mol Sci. 2020 Nov 13;21(22):. (PMID: 33202970)
      Nat Rev Gastroenterol Hepatol. 2022 Feb;19(2):87-88. (PMID: 34934180)
      Nature. 2005 Mar 3;434(7029):88-93. (PMID: 15744305)
      Cold Spring Harb Perspect Med. 2020 May 1;10(5):. (PMID: 31843875)
      J Leukoc Biol. 2013 Jan;93(1):145-54. (PMID: 23108101)
      J Virol. 2019 Feb 5;93(4):. (PMID: 30518652)
      Gut. 2019 May;68(5):893-904. (PMID: 30580250)
      J Virol. 2023 Apr 27;97(4):e0181222. (PMID: 36971565)
      Eur J Immunol. 2018 Jan;48(1):128-150. (PMID: 28872670)
      Hepatology. 2024 Jan 1;79(1):183-197. (PMID: 37540195)
      Vaccines (Basel). 2023 Mar 17;11(3):. (PMID: 36992265)
      Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):533-550. (PMID: 35595834)
    • Grant Information:
      P30 CA013330 United States CA NCI NIH HHS; R01 AI170725 United States AI NIAID NIH HHS; T32 GM007491 United States GM NIGMS NIH HHS
    • الرقم المعرف:
      0 (Antigens, CD)
      0 (alpha E integrins)
      0 (Integrin alpha Chains)
      0 (Integrin alpha1)
    • الموضوع:
      Date Created: 20241011 Date Completed: 20241023 Latest Revision: 20241031
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC11498735
    • الرقم المعرف:
      10.1371/journal.ppat.1012615
    • الرقم المعرف:
      39392861